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Abstract
Background: Epithelial cell adhesion molecule (EpCAM) is frequently and highly expressed on human carcinomas.
The emerging role of EpCAM as a signalling receptor and activator of the wnt pathway, and its expression on
tumor-initiating cells, further add to its attractiveness as target for immunotherapy of cancer. Thus far, five
conventional monoclonal IgG antibodies have been tested in cancer patients. These are murine IgG2a
edrecolomab and its murine/human chimeric IgG1 antibody version, and humanized, human-engineered and fully
human IgG1 antibodies 3622W94, ING-1, and adecatumumab (MT201), respectively. Here we compared all anti-
EpCAM antibodies in an attempt to explain differences in clinical activity and safety.
Methods: We recombinantly produced all antibodies but murine edrecolomab and investigated them for binding
affinity, EpCAM epitope recognition, ADCC and CDC, and inhibition of breast cancer cell proliferation.
Results: ING-1 and 3622W94 bound to EpCAM with much higher affinity than adecatumumab and edrecolomab.
Edrecolomab, ING-1, and 3622W94 all recognized epitopes in the exon 2-encoded N-terminal domain of EpCAM,
while adecatumumab recognized a more membrane proximal epitope encoded by exon 5. All antibodies induced
lysis of EpCAM-expressing cancer cell lines by both ADCC and CDC with potencies that correlated with their
binding affinities. The chimeric version of edrecolomab with a human Fcg1 domain was much more potent in
ADCC than the murine IgG2a version. Only adecatumumab showed a significant inhibition of MCF-7 breast cancer
cell proliferation in the absence of complement and immune cells.
Conclusion: A moderate binding affinity and recognition of a distinct domain of EpCAM may best explain why
adecatumumab showed a larger therapeutic window in cancer patients than the two high-affinity IgG1 antibodies
ING-1 and 3622W94, both of which caused acute pancreatitis.
Introduction
Epithelial cell adhesion molecule EpCAM (CD326; 17-1A
antigen) was among the first human tumor-associated
antigens discovered [1]. It was initially identified by the
monoclonal antibody (mAb) 17-1A after immunization
of mice with human colorectal cancer cells [2]. Using a
similar approach, the EpCAM antigen has been identified
many more times and each time given the name of the
respective monoclonal antibody [3,4]. For a long time,
EpCAM was considered a mere cell surface protein med-
iating homotypic cell adhesion [5-7]. This function did
not well explain its frequent and high expression in pri-
mary tumors and metastases [1,3], correlation of expres-
sion with poor survival prognosis [1,8], and its expression
on tumor-initiating or cancer stem cells [9-12]. Only
recently, EpCAM was shown to play a role in cell prolif-
eration, signal transduction, and as a proto-oncogene
[13-15]. EpCAM can undergo regulated intra-membrane
proteolysis leading to release of its small intracellular
domain EpICD [14]. In the cytoplasm, released EpICD
combines with adaptor proteins FHL2 and b-catenin ulti-
mately leading to formation of a large nuclear complex
containing transcription factor LEF/TCF, which can turn
on transcription of c-myc and cyclin genes and thereby
drive cancer and stem cell proliferation [16-20].
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immunotherapeutic approaches based on either antibodies
or vaccines [1,21]. In 2009, an anti-EpCAM trispecific
antibody called catumaxomab (Removab) obtained market
authorization in Europe for treatment of malignant ascites
in cancer patients [22]. Several other EpCAM-directed
antibodies and antibody-based constructs are at various
stages of clinical development [1,21,23]. The first mono-
clonal antibody ever tested in cancer patients was the
EpCAM-specific murine IgG2a antibody 17-1A produced
in ascites of mice [24,25]. This antibody was later pro-
duced by fermentation and called edrecolomab. Clinical
evaluation of the antibody was mainly done in patients
with colorectal cancer, either with metastatic disease [26]
or in the adjuvant setting [27]. Objective responses were
achieved only in a limited number of patients with meta-
static disease [26]. However, a pivotal study in patients
with surgically resected colorectal cancer Dukes’ stage C
randomized to observation or treatment with edrecolomab
showed a significant clinical benefit, i.e., reduction of
recurrence and death rate, and a benign safety profile
[27,28]. Subsequent larger studies in Europe and the USA
could not confirm edrecolomab’s clinical activity in the
adjuvant setting [29-31].
The high immunogenicity and short serum half life of
murine antibody edrecolomab prompted the develop-
ment of chimeric, humanized, human-engineered and
fully human anti-EpCAM antibodies all sharing the
human Fcg1 portion. The human IgG1 isotype was
selected for its superior potential of antibody-dependent
cellular cytotoxicity (ADCC) and complement-depen-
dent cytotoxicity (CDC) [32-34]. Only few patients have
been treated with a human/murine chimeric version of
edrecolomab, and then also in combination with GM-
CSF to augment effector cell function and thereby
potentially enhance the efficacy of the antibody [35,36].
The induction of an anti-idiotypic response was also
explored [36] though no positive correlation between an
anti-idiotype formation and clinical response to 17-1A
antibody could be established in more than 60 colorectal
cancer patients [37].
The human-engineered and humanized anti-EpCAM
antibodies ING-1 and 3622W94, respectively, were
developed and tested in clinical phase 1 studies in can-
cer patients [38-40]. Both had a relatively high binding
affinity for EpCAM, had a maximum tolerated dose
(MTD) of 1 mg/kg bodyweight, and their dose-limiting
toxicity was acute pancreatitis [38,39,41]. Adecatumu-
mab (MT201) is a fully human IgG1 antibody binding
with intermediate affinity to EpCAM [42]. It has so far
been administered to more than 240 patients with pros-
tate and breast cancer in two phase 1 [43-45], and two
phase 2 trials [45]. No MTD has been reached at 6 mg/
kg when delivered as monotherapy [44,46], and up to
13 mg/kg were tolerated in a phase 1 study in combina-
tion with taxotere. Of note, no clinically manifest pan-
creatitis has been observed to date. Retrospective
analyses indicated that a subgroup of patients with
metastatic breast cancer having primary tumors expres-
sing high levels of EpCAM showed clinical benefit by
adecatumumab in terms of increased time to progres-
sion and reduced incidence of new lesions [45]. When
combined with taxotere, a higher percentage of objective
responses are observed with the antibody/taxotere com-
bination than with chemotherapy alone [47].
Here, we have for the first time compared side-by-side
edrecolomab in its murine and chimeric version, ING-1,
3622W94 and adecatumumab for their in-vitro biologi-
cal characteristics, including binding affinity, epitope
recognition, ADCC and CDC, and inhibition of cancer
cell proliferation. Adecatumumab was unique in that it
bound to an epitope encoded by exon 5 of EpCAM, and
by inhibiting proliferation of MCF-7 breast cancer cells
in the absence of effector cells and complement. Our
data may help to better understand the differences in
tolerability and signs of clinical activity of the five
monoclonal antibodies.
Methods
Generation and purification of antibodies
Edrecolomab (murine anti-EpCAM; 17-1A; Panorex)
was obtained as clinical trial material produced under
G M Pu s i n gam u r i n eh y b r i d o m ac e l ll i n e( C e n t o c o r
Inc.). Human antibody adecatumumab (MT201) was
generated by phage display-guided selection and pro-
duced by CHO cells as described previously [42,48]. The
murine/human chimeric version of edrecolomab, and
3622W94 (hu323/A3) and ING-1 antibodies were gener-
ated by grafting according VH and VL DNA sequences
onto a human IgG1 backbone. VH sequences were
cloned into pEF-dhfr and VL sequences into pEF-ada
expression vectors. These antibodies were expressed in
CHO cells and purified by FPLC affinity purification
using Protein G or A. Antibodies were eluted with
100 mM citrate buffer pH 2.3.
Cell lines expressing murine, cynomolgus and human
EpCAM and respective chimera
DHFR
- Chinese hamster ovary (CHO), Kato III, MCF-7,
MCF10A cells and HEK293 cells were purchased from
the American Type Cell Culture Collection (ATCC,
Manassas, USA). CHO lines stably expressing human
EpCAM (CHO-huEpCAM), murine EpCAM (CHO-
mEpCAM), cynomolgus EpCAM (CHO-cynoEpCAM)
and the chimera of cyno/human and murine/human
EpCAM chimera were all generated by transfecting
CHO cells with expression plasmids containing the
respective cDNAs.
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In a first step, the cDNA encoding human EpCAM was
modified by introduction of three silent recognition sites
for restriction enzymes. The resulting construct allowed
convenient exchange of defined human sequence frag-
ments through their corresponding cyno equivalents in
the context of the EpCAM full-length cDNA through a
simple ‘cut-and-paste’ cloning approach. The cDNAs
encoding different human/cyno EpCAM fragments were
generated by gene synthesis. Chimeric constructs of ver-
ified DNA sequence were cloned into the pEF-dhfr
expression vector to permit transient transfection and
expression in HEK293 cells as well as stable expression
in CHO cells.
Selection of clones and amplification of expression
was performed in suspension with HyQ medium
( H y C l o n e ,L o g a n ,U S A ) ,s u p p l e m e n t e dw i t h2 0n M
methotrexate (Sigma-Aldrich, Steinheim, Germany).
Transfected CHO cells were cultured in HyQ medium
supplemented with 500 nM methotrexate at 37°C in a
5% CO2 chamber.
All in vitro assays were conducted in RPMI1640 med-
ium (Biochrom AG, Berlin, Germany) supplemented
with 10% fetal calf serum (Biochrom AG, Berlin, Ger-
many), 100 u/ml penicillin and 100 μg/ml streptomycin
(Biochrom AG, Berlin, Germany), 50 μM2 - m e r c a p -
toethanol (Invitrogen, Gaithersburg, MD), 1% non-
essential amino acids (Biochrom AG, Berlin, Germany),
1 mM sodium pyruvate (Biochrom AG, Berlin, Ger-
many), and 10 mM HEPES buffer (Biochrom AG, Berlin,
Germany). Additionally, for MCF-7 cells 10 μg/ml insu-
line (sigma) was added and MCF10A cells were cultured
as recommended by ATCC.
ADCC assay
Kato III target cells grown under regular culture condi-
tions were trypsinized for 5 min, sedimented by centrifu-
gation and resuspended in culture medium to a
concentration of 10
6 cells per ml. Cells (1 × 10
6)w e r e
labelled by incubation with BATDA (Bis-(acetoxymethyl)
2,2’:6’,2’’-terpyridine-6-6’’-dicarboxylate), the hydropho-
bic esterified form of TDA, which diffuses readily
through the cell membrane of viable cells and accumu-
lates as membrane impermeable TDA inside the target
cells due to hydrolyzation by intracellular esterases for 30
min at 37°C. After centrifugation at 350 g for 5 min cells
were washed in medium 5 times. 5000 labelled cells/well
resuspendend in medium were seeded into a 96-well
plate as targets. Separately, peripheral blood mononuc-
lear cells (PBMC) were prepared following conventional
procedures (enriched by Ficoll-Hypaque gradient centri-
fugation), washed and resuspended at 6 × 10
6 per ml.
Equal volumes of target and effector cell suspensions
were mixed resulting in a final ratio of effector to target
cells (E : T) of 50:1. This was followed by addition of an
antibody solution, previous l yd i l u t e di na1 : 4s e r i e s ,
resulting in a final concentration ranging from 0.2 to
50,000 ng/ml. Cells were then incubated for 2.5 h at
37°C. After centrifugation at 150 g and 3 min, 20 μlo f
the supernatant were added to 100 μlE u r o p i u ma n d
incubated for 10 min for chelate formation. Quantifica-
tion was performed subsequently by time-resolved
fluorometry with a plate reader (WALLAC 1420 VIC-
TOR
2). The measured signal correlates directly with the
amount of lysed cells. EC50 values are determined for
each measurement using the four-parametric logistic
regression model for the evaluation of sigmoidal dose-
response curves. All experiments were performed in
triplicate.
CDC assay
KATO III cells grown under regular culture conditions
were trypsinized for 5 min and resuspended in RPMI
medium at a concentration of 10
6 cells per ml of media.
Cells were labelled with BATDA as described in the
ADCC section. To each 160 μl of cell suspension, 20 μl
of cold human serum and 20 μlo ft h er e s p e c t i v ea n t i -
body dilution were added. Heat-inactivated human
serum was used as control. After incubation of the cell
cultures for 45 min at 25°C, cells were sedimented and
analyzed as described above in the ADCC section. All
experiments were performed in triplicates.
Epitope mapping
For standard binding analysis, 1 × 10
5 to 2 × 10
5 cells were
i n c u b a t e dw i t ht h er e s p e c t i v ea n t i b o d ya tc o n c e n t r a t i o n s
ranging from 0 to 50 μg/ml in FACS buffer in a total
volume of 50 μl for 30 min at 4°C. Thereafter, cells were
washed twice in FACS buffer and incubated with FITC-
labeled secondary antibody (Dianova Cat. No. DIA 920)
for additional 30 min at 4°C. After two washing steps in
FACS buffer, 10,000 to 20,000 events were analyzed.
Cell proliferation assay
MCF-7 and MCF10A cells grown under regular growth
conditions were trypsinized and seeded in the adequate
medium at 3,000 cells/well in a 96-well flat bottomed
plate. The following day, media was replaced with 100
μl media containing the respective antibodies at a con-
centration of 50 μg/ml. Cell proliferation was measured
at the indicated time points using either the CyQUANT
Cell Proliferation Assay Kit (Invitrogen) or Cell Prolif-
eration Reagent WST-1 (Roche) according to the manu-
facturers’ instructions.
Determination of binding constants
Biacore analysis was performed using a Biacore 3000
reader (Applied Biosystems, Uppsala, Sweden). Soluble,
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was produced and purified from the supernatant of sta-
bly transfected CHO cells [48]. EpCAM protein was
coated to CM5 flow cells (Becton Dickinson) using the
Amine Coupling Kit as described by the manufacturer.
Binding studies were performed in a running buffer con-
taining 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM
EDTA and 0.005% surfactant (P-20). KD and on/off rate
constants were determined from sensorgrams collected
with five different antibody concentrations.
Results
Binding Affinities
Binding affinities of the five recombinant antibodies was
determined by surface plasmon resonance spectroscopy
(BiaCore). Equilibrium dissociations constants (KD
values) for binding to recombinant EpCAM coated on
Biacore sensor chips were 1.5 and 2.1 μM for edrecolo-
mab and chimeric edrecolomab, respectively, 100 nM
for adecatumumab, and 190 and 160 pM for 3622W94
and ING-1, respectively (Table 1). KD values and on-
and off-rate constants confirmed earlier data showing
that 3622W94 and ING-1 were of higher affinity for
EpCAM than adecatumumab and edrecolomab. On-
rates of mAbs were rather similar, with adecatumumab
showing the fastest on-rate.T h et w oh i g h e s ta f f i n i t y
mAbs, 3622W94 and ING-1 had very slow off-rates
translating into a prolonged binding to the EpCAM
target.
Binding Domains on EpCAM
A crude mapping of binding domains on EpCAM was
done for the antibodies by using CHO cells expressing
either human, cynomolgus monkey, or two human/
monkey chimeric EpCAM proteins (Figure 1a). The two
chimeric proteins exchanged human and monkey
sequences in the middle of exon 3, which is encoding
the thyroglobulin-like repeat of EpCAM. While all four
antibodies bound to CHO cells expressing human
EpCAM in FACS analysis (Figure 1b, top panel), the
only antibody binding to all four CHO cell lines was
3622W94, indicating cross-reactivity with monkey
EpCAM. All mAbs but adecatumumab bound to cells
with a human N-terminal domain (third panel), while
adecatumumab apparently recognized the C-terminal
region 2 of human EpCAM (fourth panel).
A further mapping experiment used CHO cells
expressing chimera between human and murine
EpCAM (Figure 1c). Cells expressing murine EpCAM
were no longer bound by mAb 3622W94. Edrecolomab,
3622W94 and ING-1 all showed robust binding in
FACS to CHO cells expressing chimera that preserved
the N-terminal sequence encoded by human exon 2 (i.
e., HHM, HMH and HMM). As an example, binding of
ING-1 in FACS scans to the various transfected CHO
cells is shown in Figure 1D. Exon 2 encodes a small
sequence around amino acid position 40, which is diver-
gent between human, monkey and mouse EpCAM (Fig-
ure 1e). The underlined sequence does best explain the
differences in species crossreactivity and may therefore
represent part of the binding epitope for antibodies
3622W94, ING-1 and edrecolomab.
Binding of adecatumumab to a more C-terminal
domain of human EpCAM (see Figure 1b) was sup-
ported by analysis using the murine/human chimeric
EpCAM proteins. Only CHO cells expressing chimera
containing sequences encoded by human EpCAM exons
4-9 were bound by adecatumumab (Figure 1c).
Binding of Adecatumumab to an Exon 5-encoded
Sequence of Human EpCAM
The binding site of adecatumumab in the C-terminal
portion of EpCAM was further analyzed by HEK293 cells
expressing chimera between human and cynomolgus
EpCAM. Human and cynomolgus monkey EpCAM are
highly conserved in this portion with major deviations
Table 1 Summary of characteristics of five clinically tested anti-EpCAM monoclonal antibodies analyzed side by side
Antibody Binding Affinity
[nM]
Binding
Domain
ADCC CDC Inhibition of MCF-7 Breast Cancer
Cell Proliferation
Tolerability in
Clinical Trials
KD Kon
[M/s]
Koff
[1/s]
Mean EC50 in
[ng/ml]
Mean at 20
μg/ml[%]
Edrecolomab 1530 2.81 ×
10
4
0.043 Exon 2 264 33 Not Significant High
Chimeric
Edrecolomab
2095 1.67 ×
10
4
0.035 Exon 2 671 60 Not Significant High
3622W94 0.19 9.49 ×
10
4
1.8 ×
10
-5
Exon 2 38 70 Not Significant Low (Pancreatitis)
ING-1 0.16 1.96 ×
10
4
3.2 ×
10
-5
Exon 2 14 63 Not Significant Low (Pancreatitis)
Adecatumumab 91 3.46 ×
10
5
0.0316 Exon 5 175 29 Yes High
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tion 170 (Figure 2a). The deviating amino acids in the
monkey EpCAM protein, which is not recognized by ade-
catumumab, were changed by directed mutagenesis to
the amino acids of the human ortholog (Figure 2b).
Exchange of amino acids EEAIK in the monkey EpCAM
p r o t e i nt oQ K E I T ,a si sp r e s e n ti nt h eh u m a nE p C A M
protein, restored binding of adecatumumab to HEK293
cells (Figure 2c). The binding signal by FACS to cells
expressing the QKEIT variant of monkey EpCAM was as
strong as the signal seen with cells expressing human
EpCAM. This gain of binding identifies a small sequence
in exon 5 as the binding site for adecatumumab on
human EpCAM. Two other mu t a t i o n s ,D V Q St oD S K S
and ITNI to ITSI, did not restore binding of adecatumu-
mab to cynomolgus monkey EpCAM (Figures 2b, c).
ADCC Activity
Target cell lysis by engagement of cytotoxic, Fcg recep-
tor-expressing immune cells (ADCC) or by fixation of
complement (CDC) has been investigated for the five
clinically tested anti-EpCAM antibodies. For ADCC,
human peripheral blood mononuclear cells (PBMC)
from five different healthy human donors were co-cul-
tured with KATO III gastric carcinoma cells in the
absence or presence of increasing concentrations of
mAbs. Redirected lysis was monitored by release of a
fluorescence dye from lysed cells.
Figure 1 Mapping of binding domains of four clinically tested anti-EpCAM monoclonal antibodies by use of CHO cells expressing
cynomolgus monkey/human and murine/human chimera of EpCAM. a Structure and exon boundaries of EpCAM. Open and shaded areas
depict the subdomains used for making monkey/human chimera. b Binding of four clinically tested anti-EpCAM monoclonal antibodies to CHO
cells expressing the indicated EpCAM proteins. c Structure of human/murine EpCAM chimera and results of FACS binding analysis (right side).
Open areas show human sequences and shaded areas murine sequences. d Example of FACS binding analysis for ING-1 binding to transfected
CHO cells. FACS histograms are shown with eight CHO cell transfectants. The bold line shows binding of detection antibodies in the presence of
ING-1, the faint line binding in the absence of ING-1. MFI, mean fluorescence intensity. e Comparison of exon 2 sequences from human,
cynomolgus and murine EpCAM. The line marks the sequence stretch of highest diversity.
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as expected for non age-matched PBMC donors (Tab. 2).
ING-1 followed by 3622W94 showed the highest potency
of ADCC with a mean EC50 value for redirected lysis of
14 (0.76 nM) and 38 ng/ml (2.05 nM), respectively
(Table 2). Examples for dose response curves obtained
with two different donor PBMC are shown in Figure 3.
Close to complete lysis of target cells was observed with
PBMC from donor 1, and approximately 50% lysis with
PBMC from donor 2. Adceatumumab was also relatively
potent with a mean EC50 value for redirected lysis of
175 ng/ml (9.45 nM). While murine/human chimeric
edrecolomab was rather potent with a mean EC50 value
of 671 ng/ml (36 nM) and reaching a similar percentage
Figure 2 Mapping of the binding domain of adecatumumab to exon 5 of human EpCAM. a Comparison of exon 5 sequences from
human, cynomolgus and murine EpCAM. The lines mark sequences of highest diversity between human and cynomolgus EpCAM. b Human/
cynomolgus monkey chimera expressed on 293 cells for mapping the binding site for adeactumumab. The results of the FACS-based binding
assay are shown on the right. c FACS histograms showing the binding of adecatumumab to 293 cells expressing the EpCAM constructs shown
in b. The bold line shows binding of detection antibodies in the presence of adecatumumab, the faint line binding in the absence of the mAb.
MFI, mean fluorescence intensity.
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murine IgG2a version of edrecolomab was barely active
with PBMC from donor 1, and not active with PBMC
from donor 2 (Figure 3). Although murine edrecolomab
induced very low levels of ADCC, its mean EC50 value
was slightly lower than that of chimeric edrecolomab
(Table 2).
CDC Activity
For CDC, 10% human serum was added to KATO III
gastric carcinoma cells and cell cultures incubated for
45 min. For inactivation of complement, a fraction of
human serum was heat-treated and used as control con-
dition, along with human IgG1 and murine IgG2a iso-
type control antibodies. CDC was monitored by
fluorescent dye release from lysed cells.
All five anti-EpCAM mABs showed specific comple-
ment-mediated lysis of cancer cells in the range of 30-55%
at an antibody concentration of 20 μg/ml (Figure 4). At
2 μg/ml mAb, only the two high affinity mAbs 3622W94
and ING-1 gave CDC signals. ING-1 was the only mAb
active at 0.2 μg/ml. The two isotype control antibodies did
not show significant CDC. In all cases, no CDC was
observed with heat-treated human serum at the highest
antibody concentration of 20 μg/ml.
A Minute but Significant Impact of Effect on Breast
Cancer Cell Proliferation
EpCAM was recently shown to have oncogenic potential
and nuclear signalling activity in cancer cells [14], and to
induce upon overexpression the proliferation of quies-
cent cells via c-myc [15]. Breast cancer cell line MCF-7
Table 2 ADCC by five clinically tested anti-EpCAM monoclonal antibodies.
Antibody Half-Maximum Lysis [ng/ml]
Maximum Lysis [Percent]
Mean Half-Maximum Lysis [ng/ml] ± S.D.
Donor
12345
Edrecolomab 49 n.d. 21 917 68 264 ± 436
40% n.d. 24% 37% 16%
Chimeric Edrecolomab 277 1.910 69 515 596 671 ± 721
84% 43% 19% 94% 44%
3622W94 4.5 102 2.0 4.9 79 38 ± 48
77% 42% 43% 82% 46%
ING-1 2.6 48 0.9 8.2 10 14 ± 19
90% 47% 23% 78% 54%
Adecatumumab 50 537 11 100 176 175 ± 211
86% 39% 27% 76% 53%
Figure 3 ADCC activity of five clinically tested anti-EpCAM monoclonal antibodies. ADCC was determined by dose response analysis as
shown for 2 out of 5 human PBMC donors tested. KATO III gastric carcinoma cells were coincubated with human PBMC at an E:T ratio of 50:1
for 2.5 hours in the absence of presence of indicated mAb concentrations. Cell lysis was determined by TDA released from lysed cells chelated
with Europium and quantified by the fluorescence of the Europium-TDA chelates formed. Results from triplicate determinations and standard
deviations are shown.
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dependent on EpCAM for proliferation [13], which is
why it was here selected for further characterization of
antibodies. We tested the five mAbs at 50 μg/ml in cell
culture for effects on the metabolism of breast cancer
cell line MCF-7 and normal breast epithelial cell line
MCF10A. Only adecatumumab showed a small but sig-
nificant inhibitory effect on cell metabolism using a
WST-1 assay (data not shown). It was the only mAb that
showed after 3 days a significant 50% inhibition of MCF-
7 cell proliferation when compared to a human IgG1 iso-
type control antibody (Figure 5a and 5b). Proliferation of
normal breast epithelial cell line MCF10A was not signif-
icantly affected by any of the anti-EpCAM mAbs, includ-
ing adecatumumab (Figure 5b).
Discussion
Here we report the first side-by-side comparison of five
clinically tested anti-EpCAM monoclonal antibodies.
With the exception of adecatumumab and edrecolomab,
mAbs were newly constructed by recombinant technol-
ogy, produced by CHO cell clones and purified by a stan-
dard procedure. Their production in CHO cells may
deviate from that in cell systems used for production of
respective clinical test materials. As a consequence, cer-
tain mAbs investigated in the present study may differ in
their carbohydrate composition from the clinically tested
antibodies. Carbohydrates are known to influence ADCC
and CDC activities of antibodies [49]. Hence results from
ADCC and CDC assays have to be interpreted with cau-
tion. On the other hand, our standardized production of
mAbs may allow for a better comparison of in-vitro
properties than using clinical test samples, which are dif-
ficult to procure. N-linked carbohydrate structures as
attached to the CH2 domain of IgG may be very similar
among our four CHO-produced mAbs and, moreover,
are not expected to impact binding affinity and specificity
of the mAbs for the EpCAM antigen.
The most significant differences among edrecolomab,
3622W94, ING-1 and adecatumumab were found in their
Figure 4 CDC activity of five clinically tested anti-EpCAM monoclonal antibodies. CDC was determined for three mAb concentrations.
Human serum (10%) was added to cultures of KATO III gastric carcinoma cells and CDC after 45 min monitored by TDA released from lysed
cells chelated with Europium and quantified by the fluorescence of the Europium-TDA chelates formed. Controls included incubation with heat-
inactivated human serum, and human IgG1 and murine IgG2a isotype control antibodies. Results from triplicate determinations and standard
deviations are shown.
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derived from plasmon resonance analysis using immobi-
lized, recombinant EpCAM protein matched well with
values previously published for the mAbs. The binding
epitopes of edrecolomab, 3622W94 and ING-1 are likely
to be all contained in a short N-terminal sequence of
EpCAM encoded by exon 2. In this sequence (see Figure
1e), position 42 is most divergent and therefore may best
explain why cynomolgus EpCAM is not recognized by
edrecolomab and ING-1, but by 3622W94, which may
not depend on position 42 for binding. Future point
mutation analyses are required to define the binding epi-
topes in greater detail. The binding epitope of adecatu-
mumab was contained in a more membrane-proximal,
exon 5-encoded sequence of human EpCAM (see Figure
2). Gain of antibody binding by replacing the short
sequence EEAIK in cynomolgus EpCAM with the short
human sequence QKEIT identifies the latter as part of
the binding epitope for adecatumumab. Binding of adeca-
tumumab to a different domain of EpCAM than recog-
nized by the other mAbs apparently did not affect ADCC
or CDC activity. It may, however, affect binding of the
antibody to EpCAM on normal tissues, which may trans-
late into a higher tolerability than reported for ING-1
and 3622W94. The much slower off-rates of ING-1 and
3622W94 compared to adecatumumab and edrecolomab
may likewise determine the therapeutic window and anti-
tumor activity. High-affinity antibodies were shown to
poorly penetrate into tumor tissue while an affinity of 10
-
7-10
-8 M, as observed here for adecatumumab, was opti-
mal for tumor penetration of anti-Her-2/neu single-chain
antibodies [50].
All four human IgG1 mAbs showed robust ADCC
activity leading to similar degrees of target cell lysis at
the plateau of dose response curves. However, their
EC50 values for redirected lysis were different and
appeared to correlate with their respective binding affi-
nities as determined by plasmon resonance spectro-
scopy. In addition, EC50 values showed considerable
variation for two non age-matched PBMC donors. It has
been reported that CD56-positive natural killer (NK)
cells are the main effector population causing ADCC by
anti-EpCAM antibody adecatumumab[51]. Elder donors
were found to have higher amounts of NK cells but
Figure 5 The effect of adecatumumab on proliferation of breast cancer cell line and MCF-7 and normal breast epithelia line MCF10A.
The respective cell lines were seeded at 10
4 cells and cell numbers determined daily for three days. A human IgG1 isotype mAb and a blank
served as controls. a Results from triplicate determinations and standard deviations are shown. P values between isotype control and
adecatumumab values were determined by Student`s t-test. b The effect of five anti-EpCAM mAbs on proliferation indices of MCF-7 and MCF-
10A cell lines as percent of isotype control antibody determined by CyQUANT cell proliferation assay. Results from a representative experiment
are shown.
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Here we paid attention to using the same donor PBMC
for comparing all antibodies. Although the two PBMC
donors gave different EC50 values for ADCC for each
antibody the overall ranking of the antibodies’ ADCC
was conserved, suggesting that differences among the
antibodies were not due to donor variation but to
instrinsic properties. The murine version of edrecolo-
mab performed poorest in ADCC with human effector
cells. This may be due to a reduced compatibility of its
murine Fcg2a portion with Fcg receptors on human
immune effector cells. This notion has recently been
demonstrated by comparing ‘murinized’ IgG2a and
human IgG1 versions of adecatumumab [53].
At 20 μg/ml, all five mAbs showed robust and com-
parable levels of CDC during a 45-min assay. Only
ING-1 and 3622W94 showed CDC at lower antibody
concentrations, which again are in line with their higher
binding affinity as seen in Biacore analyses. As reported
earlier, adecatumumab and murine edrecolomab showed
equal CDC [42], whereas other investigators could not
d e t e c ta n yC D Cf o rm u r i n eo rc h i m e r i ce d r e c o l o m a b
[54]. Our data indicate that all but murine edrecolomab
should be able to eliminate cancer cells in patients by
both ADCC and CDC.
T h ef i n d i n g st h a tE p C A Mi sap r o t o - o n c o g e n ea n d
signal transducer [9,14,15] raise the possibility that anti-
EpCAM antibodies may be able to interfere with the
proliferative signal transduction cascade initiated by
EpCAM. Of all five mAbs tested, only adecatumumab
could specifically and significantly reduce proliferation
of breast cancer cell line MCF-7 but not of normal
epithelial cell line MCF10A. EpCAM knockdown experi-
ments in MCF-7 cells have shown that cells cease to
proliferate, migrate and invade soft agar, indicating that
this cancer cell line is dependent on EpCAM signalling
[13]. Future studies will investigate whether the binding
of adecatumumab to its membrane-proximal epitope
interferes with proteolytic activation of EpCAM. At the
same time, it can be studied whether murine edrecolo-
mab is promoting the proteolytic activation of EpCAM
leading to the higher proliferation index observed here
for MCF-7 cells. It is tempting to speculate that the
unique binding specificity of adecatumumab, its not
overly high affinity, robust ADCC and CDC, and its
inhibitory effect on cell proliferation may in their com-
bination be important for producing signs of clinical
activity and a good tolerability in more than 240
patients treated to date [43,45,46].
Conclusions
From the present in-vitro data, the induction of acute
pancreatitis by mAbs 3622W94 and ING-1 is best
explained by their high binding affinities for EpCAM
seen in Biacore analyses, in particular their very slow
off-rates. High binding affinities may also best explain
their superior CDC and ADCC activities at low concen-
trations. With a high affinity and slow off-rate, such
antibodies could very well reach a surface density on
cells of normal tissue, which is sufficient to trigger
ADCC and CDC reactions even if low numbers of
EpCAM molecules are accessible. Should EpCAM on
normal tissue be mostly in complex with protein part-
ners, e.g., with claudin-7, tetraspanins or CD44, high
affinity antibodies may compete for their binding to
EpCAM and permanently displace EpCAM-associated
proteins while antibodies with lower affinity should be
inefficient to do so.
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